Advanced in Endometrial Cancer

Sally E. Hay-Baron

St George Hospital
Kogarah, NSW, AU 
Advanced in Endometrial Cancer
St George Hospital
Kogarah, NSW, AU 
OverviewLocationsClinical Research

Overview

Sally Hay-Baron practices in Kogarah, Australia. Ms. Hay-Baron is rated as an Advanced expert by MediFind in the treatment of Endometrial Cancer. Her top areas of expertise are Endometrial Cancer, Breast Cancer, Osmotic Demyelination Syndrome, Peripheral Neuropathy, and Mastectomy.

Her clinical research consists of co-authoring 32 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles in the study of Endometrial Cancer.

Gender
Female

Locations

St George Hospital
Kogarah, NSW, Australia
Other Locations
Royal North Shore Hospital
St Leonards, NSW, Australia
Royal North Shore Hospital
Sydney, NSW, Australia
Melbourne, VIC, Australia
Malvern, VIC, Australia
Royal North Shore Hospital
North Shore, NSW, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3

32 Total Publications

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.
Journal: Nature communications
Published: December 23, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hay-Baron's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile